Etravirine nausea

Etravirine NNRTI 200 mg bid Take after a meal do not take on an empty stomach. Rash, nausea, diarrhea See footnote 4 for contraindicated medications. Do not administer with other NNRTIs, indinavir, atazanavir-ritonavir, fosamprenavir-ritonavir, tipranavir-ritonavir, or any unboosted PI... 

The most common symptomatic adverse effects of etravirine are rash, nausea, and diarrhea. The rash is typically mild and usually resolves after 1-2 weeks without discontinuation of therapy. Rarely, rash has been severe or life-threatening. Laboratory abnormalities include elevations in serum cholesterol, triglyceride, glucose, and hepatic transaminase levels. Transaminase elevations are more common in patients with HBV or HCV co-infection. 

Observational studies In clinical assessments of etravirine, the main adverse effects were rash, nausea, vomiting, and hypercholesterolemia [157"]. In the randomized double-blind DUET studies, rash was more common in those who took etravirine, and led to withdrawal in 2% of patients [158 ]. 

Post hoc analysis of data from the north American GRACE study found that among 204 subjects on etravirine, women experienced more nausea and rash but less diarrhoea than men with grade 3-4 hypertriglyceridaemia being more common in men. Eleven women and seven men discontinued due to side effects [235 ]. 

---